Overview

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Status:
Terminated

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

AEG35156 has shown early evidence of activity in patients with advanced indolent B-cell lymphomas in Phase 1 trials and merits further evaluation in this disease. This trial is designed to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and indolent B-cell lymphomas.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Aegera Therapeutics

Collaborator:

The Leukemia and Lymphoma Society

Treatments:

X-Linked Inhibitor of Apoptosis Protein